Acipimox-d4

Acipimox-d4 is a stable isotope labeled derivative of Acipimox, a drug commonly used to treat high levels of triglycerides and cholesterol in the blood. Acipimox-d4 is used as a reference standard in clinical and pharmaceutical research to aid in the development and testing of drugs that target lipid metabolism. Acipimox-d4 is a synthetic compound that belongs to the class of nicotinic acid derivatives. It works by inhibiting the enzyme lipoprotein lipase, which is responsible for breaking down triglycerides in the blood. As a result, the levels of triglycerides and cholesterol in the blood decrease, reducing the risk of cardiovascular disease. Chemically, Acipimox-d4 is a deuterated form of Acipimox, which means that some of the hydrogen atoms in the molecule have been replaced with deuterium atoms. This labeling technique allows researchers to track the fate of the drug in the body using mass spectrometry and other analytical techniques. Acipimox-d4 is typically administered orally in the form of tablets or capsules. The recommended dosage varies depending on the patient's condition and medical history. Common side effects of Acipimox-d4 include nausea, vomiting, and abdominal discomfort. In conclusion, Acipimox-d4 is a useful tool for researchers studying lipid metabolism and developing new drugs to treat cardiovascular disease. Its stable isotope labeling provides valuable information on the pharmacokinetics and metabolism of the drug, which can help improve patient outcomes and reduce side effects.